Search

everythinglearnresearchcommunity

for

Search:↓

Plasmacytoid dendritic cells, which overproduce IFN-α, may play a crucial role in starting alopecia areata, an autoimmune disease causing hair loss.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Certain cancer drugs interact with skin bacteria to cause acne-like rashes.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

IL-18 signaling helps mature Tregs move into the thymus.

Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.

Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.

Inflammation helps stem cells repair tissue by directing their behavior.

A man with multiple autoimmune diseases developed liver injury from azathioprine, but his liver improved after stopping the drug.

CXCL12+ fibroblasts help recruit neutrophils to fight skin infections.

Higher STAT3 levels are found in hair loss areas, but not linked to hair loss severity.

Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.

Tofacitinib may effectively treat folliculitis decalvans.

Targeting Midkine can help reduce pain and itching in keloids.

JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.

NIPP1 is important for healthy skin and could help treat skin inflammation.

Tph cells are linked to the severity of systemic lupus erythematosus.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.

Iron deficiency worsens inflammatory skin diseases by disrupting iron balance and increasing inflammation.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Ruxolitinib can cause a delayed skin reaction on the nose.

A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.